2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Highly Effective Treatment of CD38 Positive Experimental Lymphoma with Actinium-225-Daratumumab

Ottawa, ON, Canada (UroToday.com) Daratumumab is an antibody specific to CD38 and is used in treating multiple myeloma. Dr. Dawicki described a study in mice for treating CD38 tumors with Ac225-DOTA-Daratumumab. They were able to achieve 97% labeling efficiency. To study tumor uptake, the mice were injected with an imaging agent In 111-Daratumumab and followed with microSPECT/CT scans.

Tumor accumulation began within 24 hours and was complete after 7 days. Ac225-Daratumumab was injected at a dose of either 400 nCi or 200 nCi per 0.3 micrograms of antibody. Significant retardation of tumor growth and increased life expectancy were observed with a higher dose in comparison with controls. No systemic toxicity was seen in blood, kidney, or liver. Ac225-Daratumumab shows promise for the treatment of multiple myeloma.


Presented by: Wojciech Dawicki,  University of Saskatchewan

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada